Abstract：
Vaccination requires innovation to provide effective protection. Traditional vaccines have several drawbacks, which can be overcome with advanced technologies and different administration routes. Over the past 10 years, a significant amount of research has focussed on the delivery of antigens into liposomes due to their dual role as antigen-carrying systems and vaccine adjuvants able to increase the immunogenicity of the carried antigen.
This review encompasses the progress made over the last 10 years with liposome-based vaccines designed for minimally or noninvasive administration, filling the gaps in previous reviews and providing insights on composition, administration routes, results achieved, and Technology Readiness Level of the most recent formulations.
Liposome-based vaccines administered through minimally or noninvasive routes are expected to improve efficacy and complacency of vaccination programs. However, the translation from lab-scale production to large-scale production and collaborations with hospitals, research centers, and companies are needed to allow new products to enter the market and improve the vaccination programs in the future.
This review encompasses the progress made over the last 10 years with liposome-based vaccines designed for minimally or noninvasive administration, filling the gaps in previous reviews and providing insights on composition, administration routes, results achieved, and Technology Readiness Level of the most recent formulations.
Liposome-based vaccines administered through minimally or noninvasive routes are expected to improve efficacy and complacency of vaccination programs. However, the translation from lab-scale production to large-scale production and collaborations with hospitals, research centers, and companies are needed to allow new products to enter the market and improve the vaccination programs in the future.
摘要：
■疫苗接种需要创新以提供有效的保护。传统疫苗有几个缺点，可以用先进的技术和不同的给药途径来克服。在过去的10年里,大量的研究集中在将抗原递送到脂质体中,这是由于它们作为抗原携带系统和能够增加所携带抗原的免疫原性的疫苗佐剂的双重作用。
■这篇综述涵盖了在过去10年中，设计用于微创或非侵入性给药的脂质体疫苗所取得的进展。填补了以前评论中的空白，并提供了关于构图的见解，管理路线,取得的成果和最新配方的技术就绪水平。
■通过微创或非侵入途径施用的基于脂质体的疫苗有望提高疫苗接种计划的效力和自满性。然而,从实验室规模生产到大规模生产以及与医院的合作，需要研究中心和公司允许新产品进入市场，并在未来改进疫苗接种计划。
■这篇综述涵盖了在过去10年中，设计用于微创或非侵入性给药的脂质体疫苗所取得的进展。填补了以前评论中的空白，并提供了关于构图的见解，管理路线,取得的成果和最新配方的技术就绪水平。
■通过微创或非侵入途径施用的基于脂质体的疫苗有望提高疫苗接种计划的效力和自满性。然而,从实验室规模生产到大规模生产以及与医院的合作，需要研究中心和公司允许新产品进入市场，并在未来改进疫苗接种计划。
